Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for carcinomatous meningitis

Internal Medicine

Volumn 46, Issue 19, 2007, Pages 1651-1655

  Kanaji, Nobuhiro ^a   Bandoh, Shuji ^a   Nagamura, Norihiro ^a   Kushida, Yoshio ^b   Haba, Reiji ^b   Ishida, Toshihiko ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Carcinomatous meningitis; Cerebrospinal fluid; Epidermal growth factor receptor; Gefitinib; Mutation; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; DNA; TUMOR MARKER;

5' UNTRANSLATED REGION; AGED; ARTICLE; ASPIRATION PNEUMONIA; CARCINOMATOUS MENINGITIS; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DRUG RESPONSE; EXON; GENE AMPLIFICATION; HUMAN; LUMBAR PUNCTURE; LUNG ADENOCARCINOMA; LUNG NODULE; MALE; MUTATIONAL ANALYSIS; NEUROIMAGING; PHARMACOGENETICS; POSITRON EMISSION TOMOGRAPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THORAX RADIOGRAPHY; TREATMENT PLANNING; ADENOCARCINOMA; CEREBROSPINAL FLUID; GENETICS; LUNG TUMOR; MENINGITIS; METASTASIS; MUTATION; PATHOLOGY;

ADENOCARCINOMA; AGED; DNA, NEOPLASM; HUMANS; LUNG NEOPLASMS; MALE; MENINGITIS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 35448963405     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.0335     Document Type: Article

References (19)

1. Hammerer V, Pauli G, Quoix E. Retrospective study of a series of 26 carcinomatous meningitis secondary to lung cancer. Bull Cancer 92: 989-994, 2005.
2. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21: 2237-2246, 2003.
3. Cella D, Herbst RS, Lynch TJ, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 23: 2946-2954, 2005.
4. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-2520, 2005.
5. Han SW, Kim TY, Lee KH, et al. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. Lung Cancer 54: 201-207, 2006.
6. Kim MK, Lee KH, Lee JK, Choi JH, Hyun MS. Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer 50: 265-269, 2005.
7. Sakai M, Ishikawa S, Ito H, et al. Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib. Int J Clin Oncol 11: 243-245, 2006.
8. Hashimoto N, Imaizumi K, Honda T, et al. Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer. Lung Cancer 53: 387-390, 2006.
9. Janne PA, Janicek MJ, Brown F. Meningeal carcinomatosis in lung cancer. Case 2. Carcinomatous meningitis. J Clin Oncol 18: 2927-2929, 2000.
10. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev 25: 103-119, 1999.
11. Kwak EL, Jankowski J, Thayer SP, et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12: 4283-4287, 2006.
12. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11: 561-569, 1993.
13. Chiu CH, Tsai CM, Chen YM, Chiang SC, Liou JL, Perng RP. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 47: 129-138, 2005.
14. Poon AN, Ho SS, Yeo W, Mok TS. Brain metastasis responding to gefitinib alone. Oncology 67: 174-178, 2004.
15. Namba Y, Kijima T, Yokota S, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer 6: 123-128, 2004.
16. Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24: 2549-2556, 2006.
17. Hotta K, Kiura K, Tabata M, et al. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 11: 417-424, 2005.
18. Fujita J, Ueda Y, Bandoh S, Namihira H, Ishii T, Takahara J. A case of leptomeningeal metastasis from lung adenocarcinoma diagnosed by reverse transcriptase-polymerase chain reaction for carcinoembryonic antigen. Lung Cancer 22: 153-156, 1998.
19. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49: 759-772, 1982.